Advertisement
Canada markets open in 9 hours 24 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7302
    +0.0005 (+0.07%)
     

  • CRUDE OIL

    82.87
    +0.06 (+0.07%)
     

  • Bitcoin CAD

    88,041.06
    -3,229.14 (-3.54%)
     

  • CMC Crypto 200

    1,391.16
    -32.94 (-2.31%)
     

  • GOLD FUTURES

    2,325.40
    -13.00 (-0.56%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,460.50
    -204.00 (-1.15%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,703.27
    -756.81 (-1.97%)
     

  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference

NeuBase Therapeutics, Inc.
·1 min read

PITTSBURGH, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a fireside chat at the virtual Chardan 5th Annual Genetic Medicines Conference being held October 4 - 5.

Chardan 5th Annual Genetic Medicines Conference

Date:

Tuesday, October 5th

Time:

11:30 a.m. ET

Location:

Webcast link or at the company’s website

About NeuBase Therapeutics, Inc.
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com

NeuBase Investor Contact:
Daniel Ferry
LifeSci Advisors, LLC
+1 (617) 430-7576
daniel@lifesciadvisors.com

NeuBase Media Contact:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
+1 (858) 344-8091
jessica@litldog.com